NatureWise Biotech & Medicals Corporation (TPEX:4732)
Taiwan
· Delayed Price · Currency is TWD 19.50
-0.50 (-2.50%)
At close: Mar 9, 2026
TPEX:4732 Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | -37.01 | 0.9 | 10.12 | 30.02 | 30.81 | 65.32 | Upgrade
|
| Depreciation & Amortization | 11.03 | 11.01 | 10.42 | 10.8 | 11.03 | 11.68 | Upgrade
|
| Other Amortization | - | - | - | 0.14 | 0.26 | 0.38 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | -0 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | -0.44 | -0.31 | 0.08 | 0.02 | Upgrade
|
| Stock-Based Compensation | 3.23 | 5.78 | 6.83 | 1.71 | - | - | Upgrade
|
| Provision & Write-off of Bad Debts | 0.01 | -0.02 | -0 | 0.04 | - | -0.02 | Upgrade
|
| Other Operating Activities | -11.05 | -4.92 | -4.47 | -1.42 | -0.16 | -6.07 | Upgrade
|
| Change in Accounts Receivable | 6.24 | 6.68 | -1.19 | 11 | -9.6 | 5.02 | Upgrade
|
| Change in Inventory | -13.23 | -1.87 | -22.94 | -3.76 | -18.09 | 8.89 | Upgrade
|
| Change in Accounts Payable | 19.08 | -7.47 | 13.57 | -10.56 | 16.37 | -8.63 | Upgrade
|
| Change in Unearned Revenue | -0.57 | 0.84 | 1.33 | -3.15 | -0.36 | -0.97 | Upgrade
|
| Change in Other Net Operating Assets | 0.42 | -13.73 | -2.05 | -20.65 | 3.57 | 0.16 | Upgrade
|
| Operating Cash Flow | -21.86 | -2.8 | 62.2 | 13.85 | 33.72 | 55.57 | Upgrade
|
| Operating Cash Flow Growth | - | - | 349.01% | -58.92% | -39.32% | 311.94% | Upgrade
|
| Capital Expenditures | -0.72 | -0.12 | -0.31 | - | - | -0.96 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | 0.01 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | - | -0.03 | -0.33 | -0.15 | -0.18 | -0.37 | Upgrade
|
| Investment in Securities | -70.87 | 67.93 | -18.31 | -52.39 | -32.65 | -141 | Upgrade
|
| Other Investing Activities | -0.4 | -0.84 | -0.78 | 0.6 | 0.78 | -1.4 | Upgrade
|
| Investing Cash Flow | -71.98 | 66.94 | -19.72 | -51.93 | -32.05 | -143.73 | Upgrade
|
| Long-Term Debt Repaid | - | -4.54 | -4.01 | -3.94 | -3.91 | -4.07 | Upgrade
|
| Net Debt Issued (Repaid) | -4.57 | -4.54 | -4.01 | -3.94 | -3.91 | -4.07 | Upgrade
|
| Issuance of Common Stock | 0.87 | 0.77 | - | - | - | - | Upgrade
|
| Common Dividends Paid | -9.86 | -9.86 | -24.65 | -14.79 | -4.65 | - | Upgrade
|
| Other Financing Activities | 148.95 | 156.45 | - | - | - | - | Upgrade
|
| Financing Cash Flow | 108.96 | 142.83 | -28.66 | -18.73 | -8.56 | -4.07 | Upgrade
|
| Foreign Exchange Rate Adjustments | -1.9 | 0.42 | -0.25 | 0.22 | -0.12 | 0.28 | Upgrade
|
| Net Cash Flow | 13.21 | 207.4 | 13.58 | -56.59 | -7.01 | -91.96 | Upgrade
|
| Free Cash Flow | -22.58 | -2.91 | 61.9 | 13.85 | 33.72 | 54.61 | Upgrade
|
| Free Cash Flow Growth | - | - | 346.81% | -58.92% | -38.25% | 348.62% | Upgrade
|
| Free Cash Flow Margin | -12.53% | -1.30% | 38.65% | 6.06% | 13.50% | 17.79% | Upgrade
|
| Free Cash Flow Per Share | -0.46 | -0.06 | 1.24 | 0.28 | 0.68 | 1.11 | Upgrade
|
| Cash Interest Paid | 0.08 | 0.1 | 0.05 | 0.04 | 0.03 | 0.06 | Upgrade
|
| Cash Income Tax Paid | 6.81 | 0.41 | 4.24 | 1.3 | -0.02 | 0.04 | Upgrade
|
| Levered Free Cash Flow | -8.56 | 2.2 | 4.89 | 2.28 | 22.55 | 52.04 | Upgrade
|
| Unlevered Free Cash Flow | -8.52 | 2.26 | 4.92 | 2.3 | 22.57 | 52.08 | Upgrade
|
| Change in Working Capital | 11.93 | -15.54 | 39.75 | -27.12 | -8.29 | -15.73 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.